Trial Profile
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs XL 413 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 01 Apr 2022 This trial has been completed in France (End Date: 4 Aug 2010) according to European Clinical Trials Database record.
- 11 Aug 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 01 May 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.